These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37719014)

  • 61. Dual-tracer PET/CT-targeted, mpMRI-targeted, systematic biopsy, and combined biopsy for the diagnosis of prostate cancer: a pilot study.
    Qiu DX; Li J; Zhang JW; Chen MF; Gao XM; Tang YX; Zhang Y; Yi XP; Yin HL; Gan Y; Wang GL; Zu XB; Hu S; Cai Y
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2821-2832. PubMed ID: 34860277
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Substitution of l-Tryptophan by
    Günther T; Deiser S; Felber V; Beck R; Wester HJ
    J Nucl Med; 2022 Sep; 63(9):1364-1370. PubMed ID: 35027371
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Preclinical pharmacokinetic, biodistribution, imaging and therapeutic efficacy of (177)Lu-Labeled glycated bombesin analogue for gastrin-releasing peptide receptor-positive prostate tumor targeting.
    Lim JC; Cho EH; Kim JJ; Choi SM; Lee SY; Nam SS; Park UJ; Park SH
    Nucl Med Biol; 2015 Mar; 42(3):234-41. PubMed ID: 25498002
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
    Feuerecker B; Tauber R; Knorr K; Heck M; Beheshti A; Seidl C; Bruchertseifer F; Pickhard A; Gafita A; Kratochwil C; Retz M; Gschwend JE; Weber WA; D'Alessandria C; Morgenstern A; Eiber M
    Eur Urol; 2021 Mar; 79(3):343-350. PubMed ID: 33293081
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Molecular imaging and biochemical response assessment after a single cycle of [
    Rosar F; Hau F; Bartholomä M; Maus S; Stemler T; Linxweiler J; Ezziddin S; Khreish F
    Theranostics; 2021; 11(9):4050-4060. PubMed ID: 33754047
    [No Abstract]   [Full Text] [Related]  

  • 66. Synthesis and Evaluation of
    Zhao R; Ploessl K; Zha Z; Choi S; Alexoff D; Zhu L; Kung HF
    Mol Pharm; 2020 Dec; 17(12):4589-4602. PubMed ID: 33108189
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer.
    Luining WI; Cysouw MCF; Meijer D; Hendrikse NH; Boellaard R; Vis AN; Oprea-Lager DE
    Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267481
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Therapeutic efficacy, prognostic variables and clinical outcome of
    Suman S; Parghane RV; Joshi A; Prabhash K; Bakshi G; Talole S; Banerjee S; Basu S
    Br J Radiol; 2019 Dec; 92(1104):20190380. PubMed ID: 31600089
    [TBL] [Abstract][Full Text] [Related]  

  • 69.
    Pathmanandavel S; Crumbaker M; Yam AO; Nguyen A; Rofe C; Hovey E; Gedye C; Kwan EM; Hauser C; Azad AA; Eu P; Martin AJ; Joshua AM; Emmett L
    J Nucl Med; 2022 Apr; 63(4):560-566. PubMed ID: 34326127
    [No Abstract]   [Full Text] [Related]  

  • 70. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer.
    Ross JS; Sheehan CE; Fisher HA; Kaufman RP; Kaur P; Gray K; Webb I; Gray GS; Mosher R; Kallakury BV
    Clin Cancer Res; 2003 Dec; 9(17):6357-62. PubMed ID: 14695135
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing
    Khreish F; Kochems N; Rosar F; Sabet A; Ries M; Maus S; Saar M; Bartholomä M; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):103-112. PubMed ID: 32378019
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [
    Hofman MS; Emmett L; Sandhu S; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ng S; Francis RJ; Gedye C; Rutherford NK; Weickhardt A; Scott AM; Lee ST; Kwan EM; Azad AA; Ramdave S; Redfern AD; Macdonald W; Guminski A; Hsiao E; Chua W; Lin P; Zhang AY; McJannett MM; Stockler MR; Violet JA; Williams SG; Martin AJ; Davis ID;
    Lancet; 2021 Feb; 397(10276):797-804. PubMed ID: 33581798
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.
    Arsenault F; Beauregard JM; Pouliot F
    Curr Opin Support Palliat Care; 2018 Sep; 12(3):359-365. PubMed ID: 29939893
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Extended therapy with [
    Mader N; Nguyen Ngoc C; Kirkgöze B; Baumgarten J; Groener D; Klimek K; Happel C; Tselis N; Chun FKH; Grünwald F; Sabet A
    Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1811-1821. PubMed ID: 36702927
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The current status of prostate cancer treatment and PSMA theranostics.
    Uemura M; Watabe T; Hoshi S; Tanji R; Yaginuma K; Kojima Y
    Ther Adv Med Oncol; 2023; 15():17588359231182293. PubMed ID: 37424944
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The role of Ga
    Erdogan M; Sengul SS; Cetin B; Avcı M; Yagci S; Ozkoç I; Barikan DE; Yildiz M
    Ann Nucl Med; 2022 Jun; 36(6):562-569. PubMed ID: 35397091
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [(111)In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery.
    Schottelius M; Wirtz M; Eiber M; Maurer T; Wester HJ
    EJNMMI Res; 2015 Dec; 5(1):68. PubMed ID: 26608882
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
    Sartor O; de Bono J; Chi KN; Fizazi K; Herrmann K; Rahbar K; Tagawa ST; Nordquist LT; Vaishampayan N; El-Haddad G; Park CH; Beer TM; Armour A; Pérez-Contreras WJ; DeSilvio M; Kpamegan E; Gericke G; Messmann RA; Morris MJ; Krause BJ;
    N Engl J Med; 2021 Sep; 385(12):1091-1103. PubMed ID: 34161051
    [TBL] [Abstract][Full Text] [Related]  

  • 79. PSMA-RLT in Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Study.
    Banda A; Privé BM; Allach Y; Uijen MJM; Peters SMB; Loeff CC; Gotthardt M; Muselaers CHJ; Witjes JA; van Oort IM; Sedelaar JPM; Westdorp H; Mehra N; Khreish F; Ezziddin S; Sabet A; Kreissl MC; Winkens T; Seifert P; Janssen MJR; van Gemert WAM; Nagarajah J
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612293
    [TBL] [Abstract][Full Text] [Related]  

  • 80. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [
    Buteau JP; Martin AJ; Emmett L; Iravani A; Sandhu S; Joshua AM; Francis RJ; Zhang AY; Scott AM; Lee ST; Azad AA; McJannett MM; Stockler MR; Williams SG; Davis ID; Hofman MS;
    Lancet Oncol; 2022 Nov; 23(11):1389-1397. PubMed ID: 36261050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.